Supporting people with type 2 diabetes in effective use of their medicine through mobile health technology integrated with clinical care (SuMMiT-D Feasibility): a randomised feasibility trial protocol.

Clicks: 450
ID: 86493
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #19 of 442 articles by views in BMJ open

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 442 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Type 2 diabetes is common, affecting over 400 million people worldwide. Risk of serious complications can be reduced through use of effective treatments and active self-management. However, people are often concerned about starting new medicines and face difficulties in taking them regularly. Use of brief messages to provide education and support self-management, delivered through mobile phone-based text messages, can be an effective tool for some long-term conditions. We have developed messages aiming to support patients' self-management of type 2 diabetes in the use of medications and other aspects of self-management, underpinned by theory and evidence. The aim of this trial is to determine the feasibility of a large-scale clinical trial to test the effectiveness and cost-effectiveness of the intervention, compared with usual care.The feasibility trial will be a multicentre individually randomised, controlled trial in primary care recruiting adults (≥35 years) with type 2 diabetes in England. Consenting participants will be randomised to receive short text messages three times a week with messages designed to produce change in medication adherence or non-health-related messages for 6 months. The aims are to test recruitment methods, retention to the study, the feasibility of data collection and the mobile phone and web-based processes of a proposed definitive trial and to refine the text messaging intervention. The primary outcome is the rate of recruitment to randomisation of participants to the trial. Data, including patient reported measures, will be collected online at baseline and the end of the 6-month follow-up period. With 200 participants (100 in each group), this trial is powered to estimate 80% follow-up within 95% CIs of 73.8% to 85.3%. The analysis will follow a prespecified plan.Ethics approval was obtained from the West of Scotland Research Ethics Committee 05. The results will be disseminated through conference presentations, peer-reviewed journals and will be published on the trial website: www.summit-d.org (SuMMiT-D (SUpport through Mobile Messaging and digital health Technology for Diabetes)).ISRCTN13404264.
Reference Key
farmer2019supportingbmj Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Farmer, Andrew;Allen, Julie;Bartlett, Kiera;Bower, Peter;Chi, Yuan;French, David;Gudgin, Bernard;Holmes, Emily A;Horne, Robert;Hughes, Dyfrig A;Kenning, Cassandra;Locock, Louise;McSharry, Jenny;Miles, Lisa;Newhouse, Nikki;Rea, Rustam;Riga, Evgenia;Tarassenko, Lionel;Velardo, Carmelo;Williams, Nicola;Williams, Veronika;Yu, Ly-Mee;, ;
Journal BMJ open
Year 2019
DOI
10.1136/bmjopen-2019-033504
URL
Keywords
randomised controlled trial type 2 diabetes primary care feasibility study process evaluation digital health behavioural change intervention

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.